摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-1-(β-D-ribofuranosyl)-1H-benzimidazole | 22423-42-3

中文名称
——
中文别名
——
英文名称
2-chloro-1-(β-D-ribofuranosyl)-1H-benzimidazole
英文别名
2-chloro-1-β-D-ribofuranosylbenzimidazole;1-(2-chloro-benzoimidazol-1-yl)-D-1,4-anhydro-ribitol;2-chloro-1-(β-D-ribofuranosyl)benzimidazole;2-Chlor-1-<β-D-ribofuranosyl>-benzimidazol;2-Chlor-1-(β-D-ribofuranosyl)benzimidazol;2-Chlor-1-β-D-ribofuranosylbenzimidazol;2-Chloro-1-beta-D-ribofuranosylbenzimidazole;(2R,3R,4S,5R)-2-(2-chlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-chloro-1-(β-D-ribofuranosyl)-1H-benzimidazole化学式
CAS
22423-42-3
化学式
C12H13ClN2O4
mdl
——
分子量
284.699
InChiKey
INKPVXRUWGSVMM-GWOFURMSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    87.7
  • 氢给体数:
    3
  • 氢受体数:
    5

SDS

SDS:0c86452e1e8a9fd309c25faeafbe0886
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-chloro-1-(β-D-ribofuranosyl)-1H-benzimidazole 作用下, 以 为溶剂, 以80%的产率得到2-chloro-5,6-dibromo-1-(β-D-ribofuranosyl)benzimidazole
    参考文献:
    名称:
    Polysubstituted benzimidazoles as antiviral agents
    摘要:
    这项发明涉及新型多取代苯并咪唑及其组合物,以及它们在治疗病毒感染中的用途。本发明的多取代苯并咪唑和组合物对疱疹病毒家族的病毒,特别是人类巨细胞病毒(HCMV)和单纯疱疹病毒(HSV)表现出抗病毒特性。该发明的首选多取代苯并咪唑是2,5,6-三氯-1-(β-D-5-脱氧核糖呋喃糖基)苯并咪唑和2-溴-5,6-二氯-1-(5-脱氧-β-D-核糖呋喃糖基)苯并咪唑。
    公开号:
    US05360795A1
  • 作为产物:
    参考文献:
    名称:
    鉴定腺嘌呤和苯并咪唑核苷作为有效的人类集中核苷转运蛋白2抑制剂:高尿酸血症和痛风的潜在治疗方法
    摘要:
    为了检验人类浓缩核苷转运蛋白2(hCNT2)抑制剂抑制饮食嘌呤来源的血清尿酸盐水平升高的假设,我们先前将腺苷衍生物1鉴定为有效的hCNT2抑制剂(IC 50 = 0.64μM),但阻碍了进一步的研究。由于其溶解性差。在这里,我们描述了随后的研究结果,以鉴定出更多可溶和更有效的hCNT2抑制剂,从而发现了苯并咪唑核苷22,这是迄今为止报道的最有效的hCNT2抑制剂(IC 50 = 0.062μM)。化合物22口服嘌呤核苷后,可显着抑制血浆尿酸水平的升高。由于化合物22在大鼠中的口服吸收不良(F = 0.51%),因此其药理作用主要限于胃肠道。这些发现表明在胃肠道中抑制hCNT2可能是治疗高尿酸血症的有前途的方法。
    DOI:
    10.1021/acs.jmedchem.5b01884
点击查看最新优质反应信息

文献信息

  • Polysubstituted benzimidazoles as antiviral agents
    申请人:The Regents of the University of Michigan
    公开号:US05360795A1
    公开(公告)日:1994-11-01
    This invention relates to novel polysubstituted benzimidazoles and compositions and their use in the treatment of viral infections. The polysubstituted benzimidazoles and compositions of the present invention exhibit antiviral properties against viruses of the herpes family, particularly human cytomegalovirus (HCMV) and herpes simplex viruses (HSV). Preferred polysubstituted benzimidazoles of the invention are 2,5,6-Trichloro-1-(.beta.-D-5-deoxyribofuranosyl)benzimidazole and 2-bromo-5,6-dichloro-1-(5-deoxy-.beta.-D-ribofuranosyl)benzimidazole.
    这项发明涉及新型多取代苯并咪唑及其组合物,以及它们在治疗病毒感染中的用途。本发明的多取代苯并咪唑和组合物对疱疹病毒家族的病毒,特别是人类巨细胞病毒(HCMV)和单纯疱疹病毒(HSV)表现出抗病毒特性。该发明的首选多取代苯并咪唑是2,5,6-三氯-1-(β-D-5-脱氧核糖呋喃糖基)苯并咪唑和2-溴-5,6-二氯-1-(5-脱氧-β-D-核糖呋喃糖基)苯并咪唑。
  • Benzimidazole derivatives and medical uses thereof
    申请人:Kikuchi Norhiko
    公开号:US20080038242A1
    公开(公告)日:2008-02-14
    The present invention provides benzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R 1 and R 2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R 3 is H, a halogen atom, optionally substituted alkyl group or the like; R 4 and R 5 are H, a halogen atom, OH or the like; and R 6 and R X are H or OH: R Y is F or OH.
    本发明提供以下式(I)所表示的苯并咪唑衍生物或其药学上可接受的盐或前药,其对钠依赖性核苷酸转运体2具有抑制活性,并可用于与血浆尿酸水平异常相关的疾病。本发明的化合物可用于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗。在式中,n为1或2;R1和R2为H、卤素原子、氰基、可选取代烷基、可选取代芳基或类似物;R3为H、卤素原子、可选取代烷基或类似物;R4和R5为H、卤素原子、OH或类似物;R6和RX为H或OH;RY为F或OH。
  • BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1698635B1
    公开(公告)日:2011-12-14
  • Revankar,G.R.; Townsend,L.B., Journal of Heterocyclic Chemistry, 1968, vol. 5, p. 477 - 483
    作者:Revankar,G.R.、Townsend,L.B.
    DOI:——
    日期:——
  • POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:EP0556334A1
    公开(公告)日:1993-08-25
查看更多

同类化合物

[(2R,3R,4R,5R)-2-(5,6-二氯苯并咪唑-1-基)-4-羟基-5-(羟基甲基)四氢呋喃-3-基]磷酸二氢酯 BENZIMIDAVIR苯并咪唑核苷 5,6-二甲基-1-(5-O-膦酰-alpha-D-呋喃核糖基)-1H-苯并咪唑 5,6-二氯-1-β-D-呋喃核糖基苯并咪唑 2-氯-5,6-二甲基-1-beta-D-呋喃核糖基苯并咪唑 2,5-哌嗪二酮,3-甲基-6-(2-甲基丙基)-,反-(9CI) 1,3-二去氮杂腺苷 (2S,3R,4S,5R)-2-(5,6-二甲基苯并咪唑-1-基)-5-(羟基甲基)四氢呋喃-3,4-二醇 5,6-dichloro-2-<(4-chlorobenzyl)thio>-1-β-D-ribofuranosylbenzimidazole 5,6-dichloro-2-<(4-nitrobenzyl)thio>-1-β-D-ribofuranosylbenzimidazole 9-(1-β-D-arabinofuranosyl)-6-nitro-1,3-dideazapurine 9-(1-β-D-arabinofuranosyl)-1,3-dideazaadenine 1-(2,3-O-isopropylidene-β-D-ribofuranosyl)benzimidazole 1-(2,3-O-isopropylidene-α-D-ribofuranosyl)benzimidazole 2-{3-[3-(4-carbamoylpiperidin-1-yl)propoxy]benzylamino}-1-(β-D-ribofuranosyl)-1H-benzimidazole 5-chloro-1-(5-O-sulfamoyl-β-D-ribofuranosyl)-1H-benzimidazole 2-bromo-5,6-dichloro-5'-O-L-lysyl-1-β-D-ribofuranosylbenzimidazole 2-(sec-Butylamino)-5,6-dichloro-1-(beta-L-ribofuranosyl)-1H-benzimidazole 2,5-dimethyl-1-(β-D-erythropentofuranosyl)-1H-benzimidazole 1-β-D-arabinofuranosylbenzimidazole 5,6-Dichloro-1-(beta-L-ribofuranosyl)-2-((2,2,2-trifluoroethyl)amino)-1H-benzimidazole 2-(3-bromobenzylamino)-1-(β-D-ribofuranosyl)-1H-benzimidazole 5,6-dichlorobenzimidazole riboside-5'-O-triphosphate 1,3-bis(β-D-ribofuranosyl)-2-thio-5,6-dichlorobenzimidazole 5,6-dichloro-2-<<3-(trifluoromethyl)benzyl>thio>-1-β-D-ribofuranosylbenzimidazole 2-chloro-5,6-dinitro-1-(β-D-ribofuranosyl)benzimidazole 2-Morpholino-1-(β-D-ribofuranosyl)-benzimidazol 1H-Benzimidazole, 1-(5-O-(hydroxy(phosphonooxy)phosphinyl)-beta-D-ribofuranosyl)- 1H-Benzimidazole, 1-ribofuranosyl- lin.-Benzo-ATP (2R,3R,4S,5S)-2-(5,6-dichloro-2-sulfanyl-benzimidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol α-ribazole-3'-phosphate 5,6-Dichloro-2-(methylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-1H-benzimidazole (2R,3R,4S,5R)-2-(5,6-dichloro-2-methyl-benzimidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (2S,3S,4R,5R)-2-(5,6-Dichloro-2-mercapto-benzoimidazol-1-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol 1-<5'-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>-5,6-dichloro-2-mercaptobenzimidazole Benzimidazole, 2-chloro-1-beta-D-ribofuranosyl- 2-(Morpholin-4-yl)-1-pentofuranosyl-1h-benzimidazole 1-Pentofuranosyl-2-(piperidin-1-yl)-1h-benzimidazole 2-Methoxy-1-pentofuranosyl-1h-benzimidazole 2-(Methylsulfanyl)-1-pentofuranosyl-1h-benzimidazole 2-(Benzylsulfanyl)-1-pentofuranosyl-1h-benzimidazole N-Methyl-1-pentofuranosyl-1,3-dihydro-2H-benzimidazol-2-imine 1-Pentofuranosyl-1,3-dihydro-2H-benzimidazol-2-imine 1-Pentofuranosyl-1H-benzimidazol-2-ol n,n-Dimethyl-1-pentofuranosyl-1h-benzimidazol-2-amine 5,6-Dimethyl-1-pentofuranosyl-1,3-dihydro-2H-benzimidazol-2-imine 2-(Benzylsulfanyl)-5,6-dimethyl-1-pentofuranosyl-1h-benzimidazole 5,6-Dimethyl-2-(methylsulfanyl)-1-pentofuranosyl-1h-benzimidazole